Watch Corporate Video

Hetero Biopharma Organised INCON 2019 (International Conclave of Oncology) at Hyderabad

Hetero Biopharma- the biologics arm of Hetero group has organised its first “International Conclave of Oncology” (INCON 2019) part of its knowledge sharing initiative “Knowledge Beyond borders(KBB)” on 29th January 2019 at Hyderabad.

The event was organised by Medico marketing team of Hetero Biopharma under the leadership of Dr.AV Jayapala Reddy AVP& Global head Biologics Business and team.

The event was attended by Oncology KOLs of Bangladesh, along with marketing team of “Healthcare Pharmaceutical Ltd” a business partner from Bangladesh.

INCON created a platform for KOLs from both the nations to exchange the experiences on the usage of Bevacizumab in the management of various types of cancer viz Endometrial cancer, Colon cancer, Non-small cell lung cancer and breast cancer etc

Dr.Satya Suresh Attili, Sr Medical oncologist in Omega hospital Hyderabad addressed the audience as a key opinion leader on behalf on Hetero Biopharma with a session on “Bevacizumab – A story still in progress”, added by yet another KOL Dr.Malik Singaraju a Sr. Radiation oncologist, Continental hospital Hyderabad on “ Recent advances in colorectal cancer- Radiation oncologist perspective”, while Dr.Praveen Shetty DGM,Global Clinical Strategy & Medico marketing presented “Evaluation of response-Colorectal cancer”.

Speakers from Bangladesh, Prof. Dr.Md. Mokhles uddin (Professor & Head, Department of Oncology, North East Medical College, Sylhet) Prof. Dr. Mohammad Ehteshamul Haque(Professor and Head of Oncology Department, Anwer Khan Hospital, Dhaka) Brig. Gen. Prof.Dr.MD.Azizul Islam (HOD- Department of Medical oncology, Dhaka CMH cancer center, Dhaka) also shared their views on Colorectal cancer-Focus on Biological therapy, Non-small cell lung cancer-new paradigm in the management, Metastatic breast cancer management- Focus on targeted therapy.

Dr. AV Jayapala reddy briefed the vision of Hetero Biopharma and emphasized on the company’s effort to make Biosimilars as affordable solution to REACH each and every needy patients across the globe.